Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04939415 · ClinicalTrials.gov registry record · Phase 1
RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19
A Phase 1 study of COVID-19, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT04939415: Completed Phase 1 study of COVID-19, sponsored by University of California, San Diego.
NCT04939415 is a Phase 1 study of COVID-19 that has completed, run by University of California, San Diego. The registered enrollment target is 60 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04939415, a Phase 1 study of COVID-19, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate a 21-herb formula named modified Qing Fei Pai Du Tang (mQFPD) to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. This the study aims to establish the safety and feasibility of the use of mQFPD vs placebo in 66 total subjects. Subsequent trials will evaluate other therapeutics as well as the efficacy of mQFPD in a larger study population.
Primary Outcome
The Normal to Abnormal percentage reflects the percentage of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline.
Conditions Studied
Interventions
- DRUG mQFPD
- DRUG organic brown rice
Study Locations (2)
California
- University of California, Los Angeles - Los Angeles
- University of California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2022-03-13 |
| Phase | Phase 1 |
What the finished NCT04939415 record still lists
NCT04939415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which mQFPD is the first listed.
NCT04939415 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04939415 about?
NCT04939415 is a clinical study titled "RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19". This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate a 21-herb formula named modified Qing Fei Pai Du Tang (mQFPD) to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. This the study aims to...
What is the current status of trial NCT04939415?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2021-07-01. Estimated completion is 2022-03-13.
What conditions does trial NCT04939415 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04939415?
The interventions under investigation include: mQFPD (DRUG), organic brown rice (DRUG).
Who is sponsoring clinical trial NCT04939415?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04939415 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04939415's enrollment target sits among peer trials
60 233rd of 298 higher than 60 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
RECRUITING · Phase 1
-
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
ACTIVE NOT RECRUITING · Phase 1
-
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI